In vitro, TandAb can induce the specific lysis of CD19+ cell lines in the presence of T cells, and an IDO inhibitor could enhance the cytotoxicity of T cells triggered by MSC-TandAb.419 Clinical studies of IDO inhibitors in lymphomas are still lacking. This evidence concerns the gene CD19 and lymphoma.